MAPT and early-onset autosomal dominant Alzheimer disease: As the change in performance was only apparent in the presence of increased amyloid and tau, the Harvard APT might be a suitable outcome measure for measuring complex everyday functioning among cognitively unimpaired individuals with limited levels of Alzheimer's disease-related pathology.